Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia

Phase 1

Recruiting

Conditions: Steroid-refractory Diamond-Blackfan Anemia (DBA)

Interventions: Drug: Bitopertin

First Posted Date: 2023-04-25

Last Posted Date: 2025-05-31

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 30

Registration Number: NCT05828108

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Recruiting

Conditions: Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia
Cardiac Arrhythmias
Hematologic Malignancies
Mantle Cell Lymphoma
Sudden Cardiac Death
Chronic Lymphocytic Leukemia (CLL)

First Posted Date: 2023-02-13

Last Posted Date: 2025-07-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 135

Registration Number: NCT05724121

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

Active, not recruiting

Conditions: Sickle Cell Anemia
Sickle Cell Thalassemia
Sickle Cell Syndrome Variant
Hbss
Hbsc
Sickle Beta Zero Thalassemia
Sickle Beta Thalassemia
Sickle Cell Pain

First Posted Date: 2023-01-09

Last Posted Date: 2025-05-23

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 6

Registration Number: NCT05675436

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial

Not Applicable

Active, not recruiting

Conditions: Aortic Valve Failure
Valvular Heart Disease

Interventions: Device: TELLTALE BASILICA procedure

First Posted Date: 2022-12-28

Last Posted Date: 2025-04-08

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 139

Registration Number: NCT05666713

Locations: 🇺🇸
California Pacific Med Ctr, San Francisco, California, United States
🇺🇸
University of Colorado Health, Fort Collins, Colorado, United States
🇺🇸
Medstar WHC, Washington, District of Columbia, United States

and more 7 locations

Exploring Near Infrared Spectroscopy (NIRS) Technologies for Assessment of Muscle Physiology, Tissue Oxygenation, and Blood Flow in Patients With Sickle Cell Disease (SCD)

Not Applicable

Completed

Conditions: SCD

Interventions: Diagnostic Test: Non-Invasive Infrared Spectroscopy

First Posted Date: 2022-11-03

Last Posted Date: 2025-05-15

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 49

Registration Number: NCT05604547

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

Phase 2

Conditions: Immune Mediated Thrombocytopenia
Chronic GVHD
Immune Mediated Anemia

Interventions: Drug: fostamatinib

First Posted Date: 2022-08-22

Last Posted Date: 2025-07-03

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 20

Registration Number: NCT05509582

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias

Phase 2

Recruiting

Conditions: Immune Mediated Anemia
Immune Mediated Thrombocytopenia
Chronic GVHD

Interventions: Drug: fostamatinib

First Posted Date: 2022-08-16

Last Posted Date: 2025-06-04

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 20

Registration Number: NCT05502783

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Controls and Healthy Vasculature Initiative

Recruiting

Conditions: Healthy Volunteers
Vascular And Immunologic Diseases

First Posted Date: 2022-06-03

Last Posted Date: 2025-06-08

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1000

Registration Number: NCT05403151

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NHLBI-Emory Advanced Cardiac CT Reconstruction

Not yet recruiting

Conditions: Structural Heart Disease

First Posted Date: 2022-05-13

Last Posted Date: 2025-07-03

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1000

Registration Number: NCT05372627

Locations: 🇺🇸
Emory University Midtown Hospital, Atlanta, Georgia, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Phase 1

Active, not recruiting

Conditions: Sickle Cell Anemia
Beta Thalassemia

Interventions: Radiation: TBI
Drug: Hydroxyurea
Biological: briquilimab
Drug: Filgrastim (G-CSF)
Drug: Sirolimus
Biological: Alemtuzumab
Drug: Plerixafor

First Posted Date: 2022-05-03

Last Posted Date: 2025-07-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 40

Registration Number: NCT05357482

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy